|
Number of organ transplant recipients
|
n = 26 (26 out of 1,106; 2.35%)
|
|
Age (years)
|
39.5 (range 19–64)
|
|
Gender (Male)
|
n = 17 (65.4%)
|
|
Type of organ transplantation
| |
|
Kidney
|
n = 14 (53.8%)
|
|
Liver
|
n = 8 (30.8%); due to HBV cirrhosis (n = 1), HCV cirrhosis with/without HCC (n = 3), autoimmune hepatitis (n = 1), Wilson disease (n = 2), cryptogenic cirrhosis (n = 1)
|
|
Bone marrow
|
n = 4 (15.4%)
|
|
Complications after transplantation
| |
|
Graft rejection
|
n = 6 (23.1%); kidney (n = 1), liver (n = 4), bone marrow (n = 1)
|
|
Febrile neutropenia
|
n = 3 (11.5%)
|
|
Clinical/laboratory presentations
| |
|
Hyperbilirubinemia
|
n = 6 (23.1%)
|
|
Elevation of AST or ALT > 100 U/L
|
n = 18 (69.2%)
|
|
Liver function test (All 26 cases)
| |
|
AST (U/L)
|
125 (25–915)
|
|
ALT (U/L)
|
243 (34–1,974)
|
|
ALP (U/L)
|
193 (51–677)
|
|
TB (mg/dL)
|
3.4 (0.3–35.4)
|
|
Timing of anti-HEV antibody test after organ transplantation
| |
|
< 1 month
|
n = 4 (15.4%)
|
|
1 month – 1 year
|
n = 4 (15.4%)
|
|
> 1 year
|
n = 18 (69.2%): 1–3 years (n = 8; 30.8%), 3–5 years (n = 4; 15.4%), 5–10 years (n = 6; 23.1%)
|
|
Results of anti-HEV antibody test
| |
|
Positive anti-HEV IgG antibody
|
n = 11 (42.3%)
|
|
Positive anti-HEV IgM antibody
|
n = 10 (38.5%)
|
